One-Shot gene therapy could free patients from monthly eye injections
NCT ID NCT07178249
Summary
This early-stage study is testing a new one-time gene therapy called EXG202 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single treatment can safely deliver a vision-protecting protein long-term, potentially replacing the need for frequent eye injections. The study will enroll about 60 people to check the treatment's safety and see if it helps maintain their eyesight.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WET AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.